165 related articles for article (PubMed ID: 24215657)
1. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
[TBL] [Abstract][Full Text] [Related]
2. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
Giannoudis A; Wang L; Jorgensen AL; Xinarianos G; Davies A; Pushpakom S; Liloglou T; Zhang JE; Austin G; Holyoake TL; Foroni L; Kottaridis PD; Müller MC; Pirmohamed M; Clark RE
Blood; 2013 Jan; 121(4):628-37. PubMed ID: 23223357
[TBL] [Abstract][Full Text] [Related]
3. A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.
Grinfeld J; Gerrard G; Alikian M; Alonso-Dominguez J; Ale S; Valgañon M; Nteliopoulos G; White D; Marin D; Hedgley C; O'Brien S; Clark R; Goldman JM; Milojkovic D; Apperley JF; Foroni L
Br J Haematol; 2013 Dec; 163(5):631-9. PubMed ID: 24117365
[TBL] [Abstract][Full Text] [Related]
4. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
6. [H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience].
Sacha T; Czekalska S; Foryciarz K; Zawada M; Florek I; Cwynar D; Wator G; Balwierz W; Skotnicki AB
Przegl Lek; 2011; 68(4):191-5. PubMed ID: 21853672
[TBL] [Abstract][Full Text] [Related]
7. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
Cargnin S; Ravegnini G; Soverini S; Angelini S; Terrazzino S
Pharmacol Res; 2018 May; 131():244-254. PubMed ID: 29427770
[TBL] [Abstract][Full Text] [Related]
8. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Singh O; Chan JY; Lin K; Heng CC; Chowbay B
PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
[TBL] [Abstract][Full Text] [Related]
10. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
12. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
[TBL] [Abstract][Full Text] [Related]
13. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
14. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
[TBL] [Abstract][Full Text] [Related]
15. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
Kim DD; Hamad N; Lee HG; Kamel-Reid S; Lipton JH
Am J Hematol; 2014 Jun; 89(6):626-32. PubMed ID: 24619861
[TBL] [Abstract][Full Text] [Related]
16. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
17. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
18. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
20. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
Di Paolo A; Polillo M; Capecchi M; Cervetti G; Baratè C; Angelini S; Guerrini F; Fontanelli G; Arici R; Ciabatti E; Grassi S; Bocci G; Hrelia P; Danesi R; Petrini M; Galimberti S
Pharmacogenomics J; 2014 Aug; 14(4):328-35. PubMed ID: 24589908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
